PedAM
Pediatric Disease Annotations & Medicines
| Disease | multiple myeloma |
| Phenotype | C0376545|hematologic malignancies |
| Sentences | 2 |
| PubMedID- 22536060 | In conclusion, despite preclinical data and the encouraging results of bortezomib in other hematologic malignancies, with multiple myeloma shining as the hallmark of its success, treatment with bortezomib in follicular lymphoma has resulted in diverse response rates as a single agent (overall response rate 16%–41%)65 and provided questionable added benefit compared with established regimens such as rituximab, r-chop, bendamustine-rituximab, or r-cvp. |
| PubMedID- 20144801 | [incidence of second non-hematologic malignancies in patients with multiple myeloma]. |
Page: 1